| Clusterheadaches.com Message Board
(http://www.clusterheadaches.com/cgi-bin/yabb/YaBB.cgi) |
Cluster Headache Help and Support >> Medications, Treatments, Therapies >> Zyprexa/melatonin (slightly OT)
(Message started by: LeeS on Jan 23rd, 2007, 10:04am) |
|
Title: Zyprexa/melatonin (slightly OT)
Post by LeeS on Jan 23rd, 2007, 10:04am
This research is primarily to do with weight-gain in schizophrenia (and like many other preclinical research is based on rats), but it may be interesting to us, as it focuses on the relationship between two medications used increasingly for CH – olanzapine and melatonin:
Quote:Neuropsychopharmacology (2007) 32, 284–288. doi:10.1038/sj.npp.1301093;
Olanzapine-Induced Weight Gain and Increased Visceral Adiposity is Blocked by Melatonin Replacement Therapy in Rats
Murray A Raskind1,2, Brianna L Burke2, Norman J Crites2, Andre M Tapp1,2 and Dennis D Rasmussen1,2
Abstract
The atypical antipsychotic drug olanzapine increases body weight and visceral adiposity in schizophrenia. In rats, aging-associated increased body weight and visceral adiposity are reversed by administration of the pineal hormone melatonin. We asked if melatonin similarly would reverse olanzapine-induced increased weight and visceral adiposity in rats. Four groups (n=11/group) of female rats (240–250 g) were treated for 8 weeks with olanzapine, melatonin, olanzapine+melatonin, or vehicle alone in drinking water. Body weight and food and water consumption were determined weekly, locomotor activity at weeks 3 and 6, and nocturnal plasma melatonin concentration at week 7. At week 8, the rats were killed and visceral (perirenal, retroperitoneal, omental, and mesenteric) fat pads dissected and weighed. Olanzapine treatment reduced nocturnal plasma melatonin by 55% (p<0.001), which was restored to control levels by olanzapine+melatonin. Body weight increased 18% in rats treated with olanzapine alone, but only 10% with olanzapine+melatonin, 5% with melatonin alone, and 7% with vehicle control. Body weight and visceral fat pad weight increases in rats treated with olanzapine alone were greater than in each of the other three groups (all p<0.01), which were not significantly different. These results suggest that olanzapine-induced increases in body weight and visceral adiposity may be at least in part secondary to olanzapine-induced reduction of plasma melatonin levels, and that melatonin may be useful for the management of olanzapine-induced weight gain in humans
Source: http://www.nature.com/npp/journal/v32/n2/abs/1301093a.html |
|
-Lee |